AC Immune SA · NASDAQ (us_market)
Healthcare · Biotechnology · Switzerland
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-23$3.70 RISE2026-03-30$2.56 PEAK2026-04-09$3.40 76d | -30.8% 66d | Missed | Missed | — | — | +32.8% 10d | Missed |
DROP2025-10-29$3.84 RISE2026-02-20$2.52 PEAK2026-04-09$3.40 162d | -34.4% 114d | Missed | Missed | — | — | +34.9% 48d | Missed |
DROP2025-10-03$3.99 RISE2025-12-09$2.54 PEAK2026-01-13$3.70 102d | -36.3% 67d | Missed | Missed | — | — | +45.7% 35d | Missed |
DROP2025-10-03$3.99 RISE2025-10-22$2.67 PEAK2025-10-29$3.84 26d | -33.1% 19d | Missed | Missed | — | — | +43.8% 7d | Missed |
DROP2025-08-05$2.45 RISE2025-08-29$2.04 PEAK2025-10-03$3.99 59d | -16.7% 24d | Missed | Missed | — | — | +95.6% 35d | Missed |
DROP2024-12-06$3.15 RISE2025-04-21$1.48 PEAK2025-06-10$2.20 186d | -53.0% 136d | Missed | Missed | — | — | +48.6% 50d | Missed |
DROP2024-12-05$3.18 RISE2025-04-17$1.48 PEAK2025-06-10$2.20 187d | -53.5% 133d | Missed | Missed | — | — | +48.6% 54d | Missed |
DROP2024-11-29$3.40 RISE2025-04-10$1.48 PEAK2025-06-10$2.20 193d | -56.5% 132d | Missed | Missed | — | — | +48.6% 61d | Missed |
DROP2024-07-30$4.20 RISE2024-10-31$2.84 PEAK2024-11-14$3.55 107d | -32.4% 93d | Missed | Missed | — | — | +25.0% 14d | Missed |
DROP2024-06-06$4.87 RISE2024-09-06$2.99 PEAK2024-09-30$3.78 116d | -38.6% 92d | Missed | Missed | — | — | +26.4% 24d | Missed |
DROP2023-12-29$5.00 RISE2024-04-25$2.29 PEAK2024-06-06$4.87 160d | -54.2% 118d | Missed | Missed | — | — | +112.7% 42d | Missed |
DROP2023-12-29$5.00 RISE2024-02-07$2.66 PEAK2024-03-05$3.95 67d | -46.8% 40d | Missed | Missed | — | — | +48.5% 27d | Missed |
DROP2023-06-27$3.40 RISE2023-10-20$2.46 PEAK2023-12-29$5.00 185d | -27.6% 115d | Missed | Missed | — | — | +103.3% 70d | Missed |
DROP2023-06-27$3.40 RISE2023-08-02$2.77 PEAK2023-09-01$3.38 66d | -18.5% 36d | Missed | Missed | — | — | +22.0% 30d | Missed |
DROP2023-03-07$2.42 RISE2023-06-23$1.90 PEAK2023-06-27$3.40 112d | -21.5% 108d | Missed | Missed | — | — | +78.9% 4d | Missed |
1–15 / 29 1 / 2 | |||||||
No scored news yet for a sentiment trend.
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALSPresentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic
AC Immune (ACIU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenureBoard Chair, Martin Zügel, MD, to...
BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.
AC Immune (ACIU) delivered earnings and revenue surprises of +5.00% and +42.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 9.52 percent increase over losses of $(0.21) per share from the same
LAUSANNE, Switzerland — LAUSANNE, Switzerland — AC Immune SA on Thursday reported a loss of $18.9 million in its first quarter. On a per-share basis, the Lausanne, Switzerland-based company...
As a result, AC Immune will receive a $12 million milestone payment from Takeda under the partners' exclusive, worldwide option and license agreement for AC Immune's active immunotherapies targeting toxic forms of
AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy...
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12...
AC Immune SA (NASDAQ:ACIU) is one of the 7 Best Strong Buy European Stocks to Invest In. On April 7, 2026, Leerink analyst Marc Goodman said AC Immune SA (NASDAQ:ACIU) amending its collaboration with Eli Lilly for the Morphomer Tau program is “great news,” highlighting continued interest in targeting intracellular Tau for early Alzheimer’s prevention. […]
Dow futures down 0.1%. FGI Industries (NASDAQ: FGI) reported mixed results for Q4, with losses of 29 cents per share beating estimates but sales missing. Stock down 7.8% in pre-market. Other stocks moving lower in pre-market: BBGI, MFI, JTAI, RMIX, TMCR, NMG, SHMD, ANL, CABA, FUFU.
AC Immune stock gains after expansion of its agreement with LLY, adding next-generation Tau Morphomer candidates and boosting long-term Alzheimer's strategy.
Here is how AC Immune (ACIU) and Assertio (ASRT) have performed compared to their sector so far this year.
The U.S. market has experienced a notable climb, rising 1.2% in the last week and 33% over the past year, with earnings projected to grow significantly in the coming years. In such a robust market climate, identifying stocks with strong financial foundations is crucial for investors seeking value beyond established names. Penny stocks, often representing smaller or newer companies, remain an intriguing investment area despite their somewhat outdated label; they can offer surprising...
It's getting a cash infusion from its giant pharmaceutical partner.
Eli Lilly (NYSE:LLY) and AC Immune have amended their collaboration focused on Tau aggregation inhibitor small molecules for Alzheimer's disease and related neurodegenerative diseases. The updated agreement centers on a next generation Tau aggregation inhibitor program, with plans for IND enabling studies in 2026. The move extends Eli Lilly's R&D activity beyond obesity and diabetes into neurodegeneration, an area with significant unmet medical need. For investors who mostly associate Eli...
Under this amendment, AC Immune will receive a CHF10 million upfront payment and a subsequent milestone payment with Phase 1 dosing, in addition to milestones announced in a prior amendment. AC Immune is eligible for
AC Immune (ACIU) outlook: ACI-7104 Phase 2 data and mid-2026 readout, plus FY25 cash burn and dilution riskâsee key catalysts and what to do now.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ACIU | -10.74% | -7.64% | -15.29% | +55.56% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -13.71% | -1.92% | -11.84% | +42.87% |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-18 | Pfeifer Andrea | Chief Executive Officer | S Open-market sale | 10,000 | $2.79 | −$27.9K |
| 2026-04-16 | Pfeifer Andrea | Chief Executive Officer | P Open-market purchase | 10,000 | $3.14 | −$31.4K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04upcoming | 0.04 | — | — |
| 2026-04-30 | -0.14 | -0.15 | -7.14% |
| 2026-03-13 | -0.17 | -0.14 | +17.10% |
| 2025-11-04 | -0.17 | -0.16 | +7.78% |
| 2025-08-05 | -0.16 | -0.21 | -29.23% |
| 2025-04-30 | -0.21 | -0.19 | +8.21% |
| 2025-03-13 | -0.19 | -0.16 | +15.94% |
| 2024-11-05 | -0.19 | 0.05 | +125.86% |
| 2024-08-06 | 0.25 | -0.23 | -193.50% |
| 2024-05-13 | -0.12 | -0.18 | -53.19% |
| 2024-03-14 | -0.16 | -0.05 | +68.35% |
| 2023-11-03 | -0.15 | -0.18 | -16.50% |
| 2023-08-04 | -0.21 | -0.20 | +3.38% |
| 2023-04-28 | -0.22 | -0.21 | +5.83% |
| 2023-03-16 | -0.26 | -0.20 | +24.39% |
| 2022-10-28 | -0.21 | -0.16 | +23.81% |